Equities
Health CareMedical Equipment and Services
  • Price (GBX)221.40
  • Today's Change-2.40 / -1.07%
  • Shares traded3.00m
  • 1 Year change+3.26%
  • Beta0.6364
Data delayed at least 15 minutes, as of Oct 04 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Advanced Wound Care includes advanced dressings for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories, and personalized services for individuals with a stoma. Continence and Critical Care includes products and services for people with urinary continence issues related to spinal cord injuries and other causes. Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.

  • Revenue in GBP (TTM)1.68bn
  • Net income in GBP116.80m
  • Incorporated2016
  • Employees10.13k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gerresheimer AG1.67bn96.31m2.29bn11.91k23.731.858.911.363.333.3357.9642.820.58384.006.68171,666.003.423.314.634.7529.3529.725.865.940.50534.590.442542.689.547.7920.819.0023.421.68
Vitrolife AB259.84m-279.25m2.34bn1.12k--2.43--8.99-28.06-28.0626.1196.720.18363.656.163,276,182.00-19.72-4.57-20.43-4.7857.4858.38-107.41-21.892.438.480.1379--8.6024.99-1,077.41---7.953.30
Ambu A/S590.65m50.50m3.43bn4.82k76.836.0237.015.801.691.6919.8021.600.74592.187.171,140,165.006.383.817.374.6258.8859.378.555.431.5174.380.096122.897.4512.8880.65-13.006.67--
Sectra AB133.05m32.87m3.77bn1.22k121.9232.9693.6728.302.322.329.408.590.6136--3.631,503,436.0015.1615.7528.0829.5247.0164.9524.7119.59----0.0270.0026.844.0614.2516.5848.37--
SCHOTT Pharma AG & Co KgaA793.64m125.85m3.78bn4.65k29.965.8921.344.761.001.006.315.100.74344.344.07204,166.2011.82--16.42--34.18--15.90--1.06--0.1086--9.43--21.11------
Getinge AB2.45bn189.86m4.02bn11.89k22.701.8612.091.649.489.48122.36115.570.61682.487.042,839,084.004.815.316.356.9846.2747.837.798.690.645513.070.213637.8712.495.66-3.17---0.394434.49
ConvaTec Group PLC1.68bn116.80m4.54bn10.13k38.993.6016.032.710.05680.05680.81610.61560.59652.475.89165,621.004.152.364.742.7355.9655.036.964.341.272.960.4604127.293.373.18107.15-6.9312.3731.41
DiaSorin SpA971.41m140.34m4.76bn3.19k33.773.3618.744.903.013.0121.7830.310.36681.266.09359,117.205.2810.305.7811.5064.8166.7014.4021.251.8912.280.389224.71-15.6411.40-33.650.216716.49--
Amplifon SpA1.94bn135.19m4.87bn14.38k35.975.1113.122.510.71530.715310.275.030.622921.4610.96161,594.304.334.316.535.8124.5659.016.957.280.39926.120.592134.266.6510.66-12.219.0812.6815.68
Ypsomed Holding AG487.12m69.60m5.03bn2.30k72.199.1636.9110.325.745.7440.1845.260.55875.404.96238,875.007.984.4112.406.8134.4727.2614.297.380.596720.890.29320.5010.253.8652.835.448.6429.46
Carl Zeiss Meditec AG1.73bn170.02m5.17bn4.95k30.31----2.992.282.2823.14--------428,397.90--9.56--11.7255.1257.849.8413.15------34.479.8010.28-1.2018.0926.7914.87
Demant A/S2.51bn297.18m6.49bn21.50k21.836.03--2.5811.9810.92101.2343.360.71922.035.681,034,778.008.528.2711.6813.2375.4574.1411.8511.341.065.580.62440.0013.8910.0012.236.968.80--
Data as of Oct 04 2024. Currency figures normalised to ConvaTec Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

32.19%Per cent of shares held by top holders
HolderShares% Held
Artisan Partners LPas of 31 Dec 202297.98m4.78%
Black Creek Investment Management, Inc.as of 15 May 202497.82m4.77%
Capital Research & Management Co. (Global Investors)as of 31 Dec 202297.42m4.75%
FIL Investment Advisors (UK) Ltd.as of 30 Jul 202477.20m3.77%
Schroder Investment Management Ltd.as of 01 Jul 202459.59m2.91%
The Vanguard Group, Inc.as of 01 Jul 202457.02m2.78%
Massachusetts Financial Services Co.as of 01 Jul 202447.78m2.33%
abrdn Investment Management Ltd.as of 31 Dec 202243.37m2.12%
Royal London Asset Management Ltd.as of 01 Jul 202441.95m2.05%
BlackRock Investment Management (UK) Ltd.as of 15 May 202339.63m1.93%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.